JP2023521744A - 感染症における血行動態を変更する為の方法及び手段 - Google Patents

感染症における血行動態を変更する為の方法及び手段 Download PDF

Info

Publication number
JP2023521744A
JP2023521744A JP2022561206A JP2022561206A JP2023521744A JP 2023521744 A JP2023521744 A JP 2023521744A JP 2022561206 A JP2022561206 A JP 2022561206A JP 2022561206 A JP2022561206 A JP 2022561206A JP 2023521744 A JP2023521744 A JP 2023521744A
Authority
JP
Japan
Prior art keywords
peptide
aqgv
peptides
patients
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022561206A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521744A5 (https=
Inventor
ヴェンスヴォールト，ヘルト
クラーセン，エリック
レネス，ヨハン
Original Assignee
バイオテンプト ビー．ブイ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオテンプト ビー．ブイ． filed Critical バイオテンプト ビー．ブイ．
Publication of JP2023521744A publication Critical patent/JP2023521744A/ja
Publication of JP2023521744A5 publication Critical patent/JP2023521744A5/ja
Priority to JP2025187819A priority Critical patent/JP2026027378A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022561206A 2020-04-06 2021-04-06 感染症における血行動態を変更する為の方法及び手段 Pending JP2023521744A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025187819A JP2026027378A (ja) 2020-04-06 2025-11-06 感染症における血行動態を変更する為の方法及び手段

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063005999P 2020-04-06 2020-04-06
US63/005,999 2020-04-06
US202063045737P 2020-06-29 2020-06-29
US63/045,737 2020-06-29
US202063085771P 2020-09-30 2020-09-30
US63/085,771 2020-09-30
PCT/NL2021/050223 WO2021206547A1 (en) 2020-04-06 2021-04-06 Methods and means for modifying hemodynamics in infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025187819A Division JP2026027378A (ja) 2020-04-06 2025-11-06 感染症における血行動態を変更する為の方法及び手段

Publications (2)

Publication Number Publication Date
JP2023521744A true JP2023521744A (ja) 2023-05-25
JP2023521744A5 JP2023521744A5 (https=) 2024-04-11

Family

ID=75581581

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022561206A Pending JP2023521744A (ja) 2020-04-06 2021-04-06 感染症における血行動態を変更する為の方法及び手段
JP2025187819A Pending JP2026027378A (ja) 2020-04-06 2025-11-06 感染症における血行動態を変更する為の方法及び手段

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025187819A Pending JP2026027378A (ja) 2020-04-06 2025-11-06 感染症における血行動態を変更する為の方法及び手段

Country Status (9)

Country Link
US (1) US20230241155A1 (https=)
EP (1) EP4132556A1 (https=)
JP (2) JP2023521744A (https=)
KR (1) KR20230003495A (https=)
AU (1) AU2021252821A1 (https=)
CA (1) CA3174852A1 (https=)
CO (1) CO2022015018A2 (https=)
MX (1) MX2022012506A (https=)
WO (1) WO2021206547A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4021481A1 (en) * 2019-08-30 2022-07-06 Biotempt B.V. Q-er peptide
AU2021354766A1 (en) * 2020-09-30 2023-05-11 Biotempt B.V. Autophagy-inhibiting peptide and organic acid salt thereof addressing issues of vascular permeability
WO2025191033A1 (en) 2024-03-13 2025-09-18 Biotempt B.V. Per-operative treatment of post-operative complications (poc)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046569A2 (en) * 2003-04-08 2005-05-26 Biotempt B.V. Pharmaceutical compositions for the treatment of sars
WO2021066649A1 (en) * 2019-09-30 2021-04-08 Ebi Anti Sepsis B.V. Methods of treatment for modifying hemodynamics
JP2022545554A (ja) * 2019-08-30 2022-10-27 バイオテンプト・ベー・フェー Ｑ－ｅｒペプチド

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046569A2 (en) * 2003-04-08 2005-05-26 Biotempt B.V. Pharmaceutical compositions for the treatment of sars
JP2022545554A (ja) * 2019-08-30 2022-10-27 バイオテンプト・ベー・フェー Ｑ－ｅｒペプチド
WO2021066649A1 (en) * 2019-09-30 2021-04-08 Ebi Anti Sepsis B.V. Methods of treatment for modifying hemodynamics

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GUELER F. ET AL., PLOS ONE, vol. 10(1), JPN6025017877, 2015, pages 0115709, ISSN: 0005587343 *
PAUTA M. ET AL., LIVER INTERNATIONAL, vol. 35, JPN6025017879, 2015, pages 1383 - 1392, ISSN: 0005587344 *

Also Published As

Publication number Publication date
JP2026027378A (ja) 2026-02-18
MX2022012506A (es) 2023-01-16
EP4132556A1 (en) 2023-02-15
WO2021206547A1 (en) 2021-10-14
KR20230003495A (ko) 2023-01-06
CA3174852A1 (en) 2021-10-14
US20230241155A1 (en) 2023-08-03
CO2022015018A2 (es) 2022-10-31
AU2021252821A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
JP2026027378A (ja) 感染症における血行動態を変更する為の方法及び手段
Guney et al. Epithelial and endothelial expressions of ACE2: SARS-CoV-2 entry routes.
Chen et al. Angiotensin-(1-7) attenuates lung fibrosis by way of Mas receptor in acute lung injury
US12569538B2 (en) DPEP-1 binding compositions and methods of use
US20220370543A1 (en) Methods of treatment for modifying hemodynamics
AU2020337111A1 (en) Q-ER peptide
US20220288155A1 (en) Cxcr4 inhibitor for the treatment of acute respiratory distress syndrome and viral infections
CN112717122A (zh) 包含肽和病毒神经氨酸酶抑制剂的组合物
US20240016882A1 (en) Autophagy-inhibiting peptide and organic acid salt thereof addressing issues of vascular permeability
EP3969036A1 (en) Uses of a2 domain of von willebrand factor
US20210369665A1 (en) Methods of treating viral infection using protease inhibitors
CN115427056A (zh) 使用actriib配体陷阱和菲卓替尼治疗贫血的方法
US20210052701A1 (en) Methods of Treating Vascular Leakage Using CXCL12 Peptides
CN108210908A (zh) 预防和治疗药物性肾损伤的药物及其用途
Topal et al. COVID 19: The relationship among angiotensin-converting enzyme 2 (ACE 2), renin-angiotensin-aldesterone system (RAS), and chronic diseases
TWI920168B (zh) 調節宿主細胞表面與ｓａｒｓ-ｃｏｖ-２交互作用之方法
Goracy et al. discuss other cell organelles targeted by SARS-CoV-2
Varagic Articles in PresS. Am J Physiol Heart Circ Physiol (February 12, 2016). doi: 10.1152/ajpheart. 00833.2015

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20221014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251001

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251208